Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D Coverage Gap Discounts Not Linked To Price Increases In 2011 – GAO

This article was originally published in The Pink Sheet Daily

Executive Summary

GAO found the prices for high-expenditure brand-name drugs used by beneficiaries in the Medicare Part D coverage gap and by those who did not reach the gap in 2011 increased at a similar rate before and after the discount program was implemented in January 2011.

You may also be interested in...



Part D Premiums Will Increase If Manufacturers Offset Donut Hole Drug Discounts With Lower Rebates, Humana Warns

Medicare Part D beneficiary premiums will increase if drug firms try to offset new 50 percent discounts on branded drugs provided to beneficiaries in the coverage gap by reducing or eliminating the rebates paid to plans, Humana VP-Pharmacy and Clinical Integration William Fleming warned at a June 1 CMS workshop

CMS Expects Part D Rebates Will Continue Despite Donut Hole Discounts, Guidance Says

CMS addresses stakeholder concerns in final guidance on Part D donut hole discount program.

Medicare Price ‘Negotiation’ : Manufacturer Compliance Gets Tougher Enforcement Provision

As legislation authorizing Medicare price 'negotiation' clears the Senate and appears on its way toward enactment after years of efforts by US congressional Democrats, and opposition by Republicans and the pharmaceutical industry, the bill continues to be tweaked.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS073448

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel